Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A post-marketing pharmacovigilance analysis of cardiotoxicities following chimeric antigen receptor T-cell therapy using the FDA adverse event reporting system

View Full Paper
Ask AI
Bookmark
Share

Authors

CGChristopher Graham

Discussion

Loading...

Member takes

Overview

Pharmacovigilance analysis reveals arrhythmias and heart failure risks in acute lymphoblastic leukemia patients after CAR-T therapy.

Key Points

  • This analysis aims to identify cardiac adverse events associated with CAR-T therapy in hematological cancer patients.
  • Conducted a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS).
  • Identified adverse events related to CAR-T products and analyzed patient characteristics.
  • Performed disproportionality analysis using Reported Odds Ratios to identify risks associated with each CAR-T product.
  • 1362 cardiac adverse events reported associated with CAR-T therapy, with notable occurrences across various products.
  • Most frequent adverse events included arrhythmias, heart failure, and cardiac arrests.
  • Disproportionality analysis indicated higher risks of specific cardiac events by age and sex, as well as by CAR-T product.

Cite This Study

Christopher Graham (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d30ahttps://doi.org/10.1182/blood-2025-6301
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adverse Events of CD19- and BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy: An Analysis of the FDA Adverse Events Database2026
  2. 2Treatment-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Associated with CAR T-Cell Therapies: A Real-World FAERS Pharmacovigilance Study2026 · 1 citations
  3. 3Treatment-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Associated with CAR T-Cell Therapies : A Real-World FAERS Pharmacovigilance Study2026
  4. 4Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study2024 · 12 citations
  5. 5Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis2025